General Psychiatry - Articles | CARLAT PUBLISHING

Psychopharm Secrets: What Patients Won’t Tell You

November 4, 2024

Chris Aiken, MD and Kellie Newsome, PMHNP

How to assess med response when the patient reports is a poor guide: long-term mood stabilizers, sleep meds, and rapid cycling.

Research Update

Estrogen in Schizophrenia

November 1, 2024

Sarah Azarchi, MD

Sarah Azarchi, MD. Dr. Azarchi has no financial relationships with companies related to this material.

Estrogen therapy may improve schizophrenia symptoms in women, highlighting its potential role as an adjunctive treatment.

Research Update

Overdiagnosis of ADHD

November 1, 2024

Alvin Marquez, MD

Alvin Marquez, MD. Dr. Marquez has no financial relationships with companies related to this material.

A recent study reveals the limitations of ADHD screening tools, highlighting the risks of overdiagnosis in adults based on self-reports.

Research Update

Lithium, Valproate Have Low (and Similar) Risk of Kidney Injury

November 1, 2024

Alex Evans, PharmD, MBA.

Alex Evans, PharmD, MBA. Dr. Evans has no financial relationships with companies related to this material.

Research explores the kidney injury risks associated with lithium compared to valproate, revealing unexpected findings.

Research Update

Esketamine vs Quetiapine in Treatment-Resistant Depression

November 1, 2024

Ivy Song, MD

Ivy Song, MD. Dr. Song has no financial relationships with companies related to this material.

Esketamine outperforms quetiapine in TRD remission rates, but the clinical significance of this difference remains uncertain.

Expert Q&A

Antipsychotics Reconsidered

November 1, 2024

Harish Kavirajan, MD

Harish Kavirajan, MD

Psychiatrist in private practice. Associate Professor of Clinical Psychiatry, University of California Irvine, Irvine, CA.

Dr. Kavirajan has no financial relationships with companies related to this material.

Harish Kavirajan revisits the use of antipsychotics in depression, weighing small benefits against serious risks, like tardive dyskinesia and metabolic issues.

News of Note

Azstarys: Vyvanse’s Dexmethylphenidate Cousin

November 1, 2024

Chris Aiken, MD

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report.

Dr. Aiken has no financial relationships with companies related to this material.

Azstarys is methylphenidate's answer to Vyvanse. But how does its abuse potential compare?

Expert Q&A

How to Stop a Psychiatric Med

November 1, 2024

Mark Horowitz, MBBS, PhD

Mark Horowitz, MBBS, PhD

Research and Development Department, Goodmayes Hospital, North East London NHS Foundation Trust, Essex, UK; Visiting Lecturer in Psychopharmcology, King’s College London. Co-author of The Maudsley Deprescribing Guidelines (Wiley-Blackwell; 2024).

Dr. Horowitz is cofounder and consultant for Outro Health. Dr. Aiken has reviewed this educational activity and has determined that there is no commercial bias as a result of this financial relationship.

Dr. Horowitz explains the principle, practicalities, and science of tapering psychiatric medications.

Clinical Update

Vyvanse Goes Generic: An Amphetamine Apart

November 1, 2024

David Liebers, MD and Chris Aiken, MD

David Liebers, MD. Psychiatry resident at NYU Langone, Department of Psychiatry.

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Dr. Liebers and Dr. Aiken have no financial relationships with companies related to this material.

Known for lower misuse potential and a smoother effect profile, lisdexamfetamine stands out in ADHD treatment. This article explores what makes it unique among stimulants.